Aurobindo Pharma ki EU mein dhamakedaar entry, USFDA se bhi good news! Share price ne pakdi raftaar

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Aurobindo Pharma ki EU mein dhamakedaar entry, USFDA se bhi good news! Share price ne pakdi raftaar
Overview

Aurobindo Pharma ke liye aaj double dhamaka hua hai! Pehle toh unki subsidiary ne Europe mein biosimilars bechne ki ek badi deal sign ki hai, aur upar se USFDA se bhi VAI classification mil gaya. Is sab ka asar stock price par dikha aur share thoda upar chala gaya.

Europe mein biosimilars ka naya khel shuru!

Aurobindo Pharma ab Europe ke biosimilars market mein apna pair jama rahi hai. Unki subsidiary CuraTeQ Biologics ne Europe ki company STADA Arzneimittel AG ke saath ek marketing aur distribution deal ki hai. Is deal ke through, do EMA-approved biosimilars Europe ke select markets mein launch honge. Ye move company ko Europe ke ek bade aur fast-growing sector mein entry dilayega. &

Dekha jaye toh, yeh European biosimilars market 2025 tak $16.2 billion ka hone ka andaza hai aur aage 2034 tak 15.75% ke CAGR se badhne ki ummeed hai. Is partnership se CuraTeQ, STADA ke strong distribution network ka fayda utha payegi aur market mein apni jagah bana payegi. Europe mein health systems ne 2006 se ab tak €50 billion se zyada ki savings ki hai, isiliye biosimilars ki demand kaafi hai.

STADA aur CuraTeQ ka power combo!

CuraTeQ, jo ki Aurobindo ki subsidiary hai, oncology aur immunology ke biosimilars par focus karti hai. Unke paas already Dyrupeg aur Zefylti ke liye EMA approvals hain, aur Bevqolva ke liye MHRA approval hai. STADA Arzneimittel AG ki baat karein toh, unhone fiscal year 2025 mein €4,296 million ki group sales report ki hai, aur unke specialty pharma segment mein biosimilar sales mein double-digit growth dikha hai.

USFDA inspection ka bhi update!

Europe ki deal ke saath saath, Aurobindo Pharma ko USFDA se bhi ek achi khabar mili hai. Unki Indian subsidiary Apitoria Pharma ki Unit-V facility ka USFDA inspection khatam ho gaya hai aur use Voluntary Action Indicated (VAI) classification mila hai. Iska matlab hai ki inspection band ho gaya hai aur USFDA abhi koi immediate enforcement action nahi legi. Ye ek positive sign hai, especially jab recently ek doosri subsidiary Eugia Pharma ko ek OAI (Official Action Indicated) mila tha.

Analysts kya keh rahe hain?

Experts aur analysts ka Aurobindo Pharma par general outlook positive hai. Average 12-month price target ₹1,385.00 ke aas-paas hai. JM Financial ne toh 'BUY' rating dekar target ₹1,610 rakha hai, aur FY26 se FY28 ke beech revenue, EBITDA, aur PAT mein achi growth predict ki hai (17%, 21%, 26% CAGR). Unhe lagta hai ki stock abhi undervalued hai.

Kal, March 25, 2026 ko, Aurobindo Pharma ka share ₹1,308.00 par band hua, jo 2.09% ka jump tha.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.